Cover Image
市場調查報告書

細胞分裂週期7同源體蛋白激酶:開發中產品分析

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 365750
出版日期 內容資訊 英文 31 Pages
訂單完成後即時交付
價格
Back to Top
細胞分裂週期7同源體蛋白激酶:開發中產品分析 Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Pipeline Review, H2 2017
出版日期: 2017年08月29日 內容資訊: 英文 31 Pages
簡介

本報告提供以細胞分裂週期7同源體蛋白激酶為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

細胞分裂週期7同源體蛋白激酶 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Amgen Inc.
  • Millennium Pharmaceuticals, Inc.
  • ProNAi Therapeutics, Inc.
  • SBI Biotech Co., Ltd.

藥物簡介

暫停中的計劃

開發中止的產品

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0997TDB

Summary:

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Cell division cycle 7-related protein kinase is an enzyme encoded by the CDC7 gene. It phosphorylate substrates that regulate the G1/S phase transition and DNA replication. Overexpression of CDC7 is associated with neoplastic transformation for some tumors.

Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) pipeline Target constitutes close to 8 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase I, Preclinical and Discovery stages are 2, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology which include indications Solid Tumor, Pancreatic Cancer, Blood Cancer, Ovarian Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Colorectal Cancer, Esophageal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Leukemias, Lymphoma, Melanoma, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer and Transitional Cell Cancer (Urothelial Cell Cancer).

The latest report Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Pipeline Review, H2 2017, outlays comprehensive information on the Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)
  • The report reviews Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Overview
    • Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
    • Eli Lilly and Company
    • Millennium Pharmaceuticals Inc
    • Nerviano Medical Sciences Srl
    • Sierra Oncology Inc
    • Takeda Pharmaceutical Company Ltd
  • Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Drug Profiles
    • LBS-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LY-3143921 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MSK-777 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit CDC7 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CDC-7 for Pancreatic Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CDC7 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SRA-141 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAK-931 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Dormant Products
  • Cell Division Cycle 7 Related Protein Kinase (CDC7 or EC 2.7.11.1) - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indication, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by Eli Lilly and Company, H2 2017
  • Pipeline by Millennium Pharmaceuticals Inc, H2 2017
  • Pipeline by Nerviano Medical Sciences Srl, H2 2017
  • Pipeline by Sierra Oncology Inc, H2 2017
  • Pipeline by Takeda Pharmaceutical Company Ltd, H2 2017
  • Dormant Projects, H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
Back to Top